Ocugen’s COVID-19 Vaccine Co-Development Partner, Bharat Biotech, Shares Phase 3 Results Demonstrating 77.8% Protection against Overall Disease - Yahoo Finance
- Ocugen’s COVID-19 Vaccine Co-Development Partner, Bharat Biotech, Shares Phase 3 Results Demonstrating 77.8% Protection against Overall Disease Yahoo Finance
- India's homegrown Covid-19 vaccine has 78% efficacy against symptomatic infections, developer says CNN
- Covaxin Phase 3 trial data out; gives an efficacy of 77.8% against symptomatic Covid-19 TIMES NOW
- India's Bharat Biotech says vaccine 93.4% effective against severe COVID-19 Yahoo News
- The Latest: Indian-made vaccine works against all variants ABC News
- View Full Coverage on Google News
source https://news.google.com/__i/rss/rd/articles/CBMiSGh0dHBzOi8vZmluYW5jZS55YWhvby5jb20vbmV3cy9vY3VnZW4tY292aWQtMTktdmFjY2luZS1jby0yMTQyMDAzNjAuaHRtbNIBUGh0dHBzOi8vZmluYW5jZS55YWhvby5jb20vYW1waHRtbC9uZXdzL29jdWdlbi1jb3ZpZC0xOS12YWNjaW5lLWNvLTIxNDIwMDM2MC5odG1s?oc=5
Comments
Post a Comment